Safia K Ahmed1, R Lor Randall2, Steven G DuBois3, William S Harmsen4, Mark Krailo5, Karen J Marcus6, Katherine A Janeway3, David S Geller7, Joel I Sorger8, Richard B Womer9, Linda Granowetter10, Holcombe E Grier3, Richard G Gorlick11, Nadia N I Laack12. 1. Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota. 2. Department of Orthopedics, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah. 3. Department of Pediatrics, Dana-Farber/Boston Children's Cancer and Blood Disorders Center & Harvard Medical School, Boston, Massachusetts. 4. Department of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota. 5. Department of Preventative Medicine, University of Southern California, Los Angeles, California. 6. Department of Radiation Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center & Harvard Medical School, Boston, Massachusetts. 7. Department of Pediatrics and Orthopedic Surgery, Montefiore Medical Center & Albert Einstein College of Medicine, Bronx, New York. 8. Department of Pediatrics, Cincinnati Children's Hospital, Cincinnati, Ohio. 9. Department of Pediatrics, University of Pennsylvania, Perelman School of Medicine & Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 10. Department of Pediatrics, New York University (NYU) Medical School and NYU Langone Medical Center, New York, New York. 11. Division of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, Texas. 12. Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota. Electronic address: laack.nadia@mayo.edu.
Abstract
PURPOSE: To identify clinical and treatment variables associated with a higher risk of local failure in Ewing sarcoma patients treated on recent Children's Oncology Group protocols. METHODS AND MATERIALS: Data for 956 patients treated with ifosfamide and etoposide-based chemotherapy on INT-0091, INT-0154, and AEWS0031 were analyzed. Local treatment modalities were defined as surgery, definitive radiation therapy (RT), or surgery plus radiation (S+RT). Five-year cumulative incidence of local failure was determined. RESULTS: The local failure rate for the entire cohort was 7.3%, with a 3.9% rate for surgery, 15.3% for RT (P<.01), and 6.6% for S+RT (P=.12). The local failure incidence was 5.4% for extremity tumors, 13.2% for pelvis tumors (P<.01), 5.3% for axial non-spine tumors (P=.90), 9.1% for extraskeletal tumors (P=.08), and 3.6% for spine tumors (P=.49). The incidence of local failure was 14.8% for extremity tumors and 22.4% for pelvis tumors treated with RT, compared with 3.7% for extremity tumors and 3.9% for pelvis tumors treated with surgery (P≤.01). There was no difference in local failure incidence by local treatment modality for axial non-spine, spine, and extraskeletal tumors. The local failure incidence was 11.9% in patients aged ≥18 years versus 6.7% in patients aged <18 years (P=.02). Age ≥18 years (hazard ratio 1.9, P=.04) and treatment with RT (hazard ratio 2.40, P<.01) remained independent prognostic factors for higher local failure incidence on multivariate analysis. Tumor size (</≥ 8 cm) was available in 40% of patients and did not correlate with local failure incidence. CONCLUSIONS: Local tumor control is excellent and similar between surgery and RT for axial non-spine, spine, and extraskeletal tumors. Age ≥18 years and use of RT, primarily for pelvis and extremity tumors, are associated with the highest risk of local failure. Further efforts should focus on improving outcomes for these patients.
PURPOSE: To identify clinical and treatment variables associated with a higher risk of local failure in Ewing sarcomapatients treated on recent Children's Oncology Group protocols. METHODS AND MATERIALS: Data for 956 patients treated with ifosfamide and etoposide-based chemotherapy on INT-0091, INT-0154, and AEWS0031 were analyzed. Local treatment modalities were defined as surgery, definitive radiation therapy (RT), or surgery plus radiation (S+RT). Five-year cumulative incidence of local failure was determined. RESULTS: The local failure rate for the entire cohort was 7.3%, with a 3.9% rate for surgery, 15.3% for RT (P<.01), and 6.6% for S+RT (P=.12). The local failure incidence was 5.4% for extremity tumors, 13.2% for pelvis tumors (P<.01), 5.3% for axial non-spine tumors (P=.90), 9.1% for extraskeletal tumors (P=.08), and 3.6% for spine tumors (P=.49). The incidence of local failure was 14.8% for extremity tumors and 22.4% for pelvis tumors treated with RT, compared with 3.7% for extremity tumors and 3.9% for pelvis tumors treated with surgery (P≤.01). There was no difference in local failure incidence by local treatment modality for axial non-spine, spine, and extraskeletal tumors. The local failure incidence was 11.9% in patients aged ≥18 years versus 6.7% in patients aged <18 years (P=.02). Age ≥18 years (hazard ratio 1.9, P=.04) and treatment with RT (hazard ratio 2.40, P<.01) remained independent prognostic factors for higher local failure incidence on multivariate analysis. Tumor size (</≥ 8 cm) was available in 40% of patients and did not correlate with local failure incidence. CONCLUSIONS:Local tumor control is excellent and similar between surgery and RT for axial non-spine, spine, and extraskeletal tumors. Age ≥18 years and use of RT, primarily for pelvis and extremity tumors, are associated with the highest risk of local failure. Further efforts should focus on improving outcomes for these patients.
Authors: A Raciborska; K Bilska; K Drabko; E Michalak; R Chaber; M Pogorzała; K Połczyńska; G Sobol; M Wieczorek; K Muszyńska-Rosłan; M Rychlowska-Pruszyńska; C Rodriguez-Galindo; M Dziuk Journal: Clin Transl Oncol Date: 2015-08-07 Impact factor: 3.405
Authors: Bradley J Stish; Safia K Ahmed; Peter S Rose; Carola A Arndt; Nadia N Laack Journal: Pediatr Blood Cancer Date: 2015-08-14 Impact factor: 3.167
Authors: A Schuck; J Hofmann; C Rübe; A Hillmann; S Ahrens; M Paulussen; H Jürgens; J Dunst; N Willich Journal: Int J Radiat Oncol Biol Phys Date: 1998-12-01 Impact factor: 7.038
Authors: Carlos Rodriguez-Galindo; Catherine A Billups; Larry E Kun; Bhaskar N Rao; Charles B Pratt; Thomas E Merchant; Victor M Santana; Alberto S Pappo Journal: Cancer Date: 2002-01-15 Impact factor: 6.860
Authors: Safia K Ahmed; Steven I Robinson; Carola A S Arndt; Ivy A Petersen; Michael G Haddock; Peter S Rose; Nadia N Issa Laack Journal: Pediatr Blood Cancer Date: 2017-02-28 Impact factor: 3.167
Authors: Daniel J Indelicato; Sameer R Keole; Amir H Shahlaee; Wenyin Shi; Christopher G Morris; Robert B Marcus Journal: Int J Radiat Oncol Biol Phys Date: 2008-05-01 Impact factor: 7.038
Authors: M A Tucker; G J D'Angio; J D Boice; L C Strong; F P Li; M Stovall; B J Stone; D M Green; F Lombardi; W Newton Journal: N Engl J Med Date: 1987-09-03 Impact factor: 91.245
Authors: Bivas Biswas; Shishir Rastogi; S A Khan; B K Mohanti; D N Sharma; M C Sharma; A R Mridha; Sameer Bakhshi Journal: J Bone Joint Surg Am Date: 2014-05-21 Impact factor: 5.284
Authors: Simone de Campos Vieira Abib; Chan Hon Chui; Sharon Cox; Abdelhafeez H Abdelhafeez; Israel Fernandez-Pineda; Ahmed Elgendy; Jonathan Karpelowsky; Pablo Lobos; Marc Wijnen; Jörg Fuchs; Andrea Hayes; Justin T Gerstle Journal: Ecancermedicalscience Date: 2022-02-17
Authors: Dana L Casey; Kenneth L Pitter; Leonard H Wexler; Emily K Slotkin; Gaorav P Gupta; Suzanne L Wolden Journal: Br J Cancer Date: 2021-05-20 Impact factor: 7.640
Authors: Andrew J Bishop; J Andrew Livingston; Matt S Ning; Isaac D Valdez; Cody A Wages; Mary Fran McAleer; Arnold C Paulino; David R Grosshans; Kristina D Woodhouse; Randa Tao; Michael E Roth; G Brandon Gunn; Susan L McGovern Journal: Int J Radiat Oncol Biol Phys Date: 2021-03-04 Impact factor: 8.013
Authors: Michael J Yang; Ros Whelan; Jennifer Madden; Jean M Mulcahy Levy; B K Kleinschmidt-DeMasters; Todd C Hankinson; Nicholas K Foreman; Michael H Handler Journal: Childs Nerv Syst Date: 2017-12-28 Impact factor: 1.475
Authors: Augustine M Saiz; Alicia A Gingrich; Robert J Canter; Amanda R Kirane; Arta M Monjazeb; R Lor Randall; Steven W Thorpe Journal: Sarcoma Date: 2019-04-24
Authors: Gregory C Stachelek; John A Ligon; Jennifer Vogel; Adam S Levin; Nicolas J Llosa; Brian H Ladle; Christian F Meyer; Stephanie A Terezakis; Carol D Morris; Matthew M Ladra; Christine A Pratilas Journal: Sarcoma Date: 2021-04-17